ADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.

ADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What are the allegations?

Shareholders allege that ADMA Biologics, Inc. (ADMA) misled investors regarding its business operations. According to the complaint, during the class period, defendants made false and/or misleading statements and/or failed to disclose that: